Tower Saint John’s Imaging conducted their successful Toy Drive benefiting the following organizations:
40% of women have dense breast tissue and for these women, mammography screenings alone may not be enough to find breast cancer. Both cancer and dense tissue appear white on a mammogram, enabling cancer to hide.
Speaking on the benefits of utilizing Automated Breast Ultrasound to help detect cancer in dense breasts, Tower Imaging Medical Group’s Dr. Daniel Kirsch was quoted as saying, “We implement ABUS because it offers a true advance in screening ultrasound evaluation of the breast.”
Dr. Kirsch further elaborated by stating, “Studies have shown that tomosynthesis can improve cancer detection, and decrease recall rates or false positives. With the ability to see through overlapping tissue, tomosynthesis also provides improved localization and characterization of masses,” said Arnold Honick, MD, Radiologist, RCI, PLC, Radiology Consultants of Iowa in Cedar Rapids, Iowa. “However, tomosynthesis is still X-ray based and sensitivity is reduced in women with extremely dense breasts, which means that some masses will still be masked and likely not detected. This is where ABUS, utilizing a different imaging technology, is complementary to mammography and can improve overall screen-detected breast cancer.”
To view more information about Automated Breast Ultrasound, and read more about Dr. Kirsch’s statement of benefits, view the full article on Aunt Minnie’s site here: https://www.auntminnie.com/index.aspx?sec=eba&sub=eml&pag=dis&itemId=121950&muid=10866708
Contact Tower Saint John’s Imaging at 310.264.9000 to schedule an ABUS exam.
Speaking on the ever-challenging environment in the radiology services industry, Tower Imaging Group’s Dr. Bruce Yawitz was featured and quoted in www.radiologybusiness.com discussing how radiology facilities can adapt and survive the present day’s many business challenges.
Speaking on Tower Imaging’s strategical objectives, he was quoted as saying, “We pride ourselves on being a specialty-based, small boutique group, but these days I don’t think that’s enough,” says Bruce Yawitz, MD, president of Tower Imaging. “We need to have a bigger footprint, and sharing assets with other like-minded groups under the umbrella of Strategic Radiology will provide everything that’s important to our hospital partners, while allowing us to maintain the independence we’ve always cherished.”
To view the complete article, please go to the following link: Go Big or Go Bust? How Less-than-Large Radiology Practices Can Survive the Consolidation Era
This innovative PET/CT imaging system from GE Healthcare may help you increase your diagnostic confidence and enhance the care of your patients. The Discovery MI DR PET/CT uses advanced detector technology and compared to previous scanners, can deliver:
The Discovery™ MI DR PET/CT imaging system from GE Healthcare uses revolutionary LightBurst detector technology to improve scanning speed and diagnostic accuracy.
In addition to faster scanning times, this scanner will allow lower radiation dosing with new state-of-the-art LYSO detectors. Discovery MI DR was created to help clinicians diagnose and stage disease earlier and better guide treatment strategies while enabling more compelling research with more novel, faster decaying tracers. This system also features the latest diagnostic CT innovations to provide a “one-stop-shop” diagnostic experience.
With the Discovery MI DR system, we continue to raise the level of excellence in healthcare in our area. We are proud to be on the leading edge of advancing the quality of cancer and cardiac care for our local, regional and international patients.
See how this remarkably advanced PET/CT system can help make a difference in patient care by calling us at 310.264.9000 and requesting more info!
John F. Thompson, MD,*1 Lauren E. Haydu, PhD,1 Roger F. Uren, MD1, Robert H. Andtbacka, MD2, Jonathan S. Zager, MD3, Peter D. Beitsch, MD4, Doreen Agnese, MD5, Nicola Mozzillo, MD6, Alessandro Testori, MD7, Tawnya L. Bowles, MD8, Harald J. Hoekstra, MD, PhD9, Mark C. Kelley, MD10, Jeffrey Sussman, MD11, Schlomo Schneebaum, MD12, B. Mark Smithers, MBBS13, Gregory McKinnon, MD14, Eddy Hsueh, MD15, Lisa Jacobs, MD16, Erwin Schultz, MD17, Douglas Reintgen, MD3, John M. Kane, MD18, Erica B. Friedman, MD1, Hejing Wang, MD19, Lisa Van Kreuningen, MS20, Vicki Schiller, MD21, David A. Elashoff, PhD19, Robert Elashoff, MD19, Alistair J. Cochran, MD19, Stacey Stern, MS20, Mark B Faries MD20, and the MSLT-II Trial Group
1Melanoma Institute Australia, The University of Sydney, 2Huntsman Cancer Institute, 3H. Lee Moffitt Cancer Center, 4Dallas Surgical Group, 5Ohio State University, 6Istituto Nazionale dei Tumori Napoli, 7Istituto Europeo de Oncologia, 8IHC Cancer Services – Intermountain Medical Center, 9University Medical Center Groningen, 10Vanderbilt University, 11University of Cincinnati, 12Tel-Aviv Sourasky Medical Center, 13Princess Alexandra Hospital, 14Tom Baker Cancer Centre, 15Saint Louis University, 16Johns Hopkins Medical Institute, 17City Hospital of Nürnberg, Paracelsus Medical University, 18Roswell Park Comprehensive Cancer Center, 19University of California at Los Angeles; 20John Wayne Cancer Institute, 21Providence St John’s Health Center
Corresponding author:
John F Thompson MD
Melanoma Institute Australia
40 Rocklands Road
NORTH SYDNEY NSW 2060
AUSTRALIA
Tel: +612 9911 7366
E: john.thompson@melanoma.org.au
ABSTRACT
Introduction: It has been suggested that preoperative ultrasound (US) assessment of regional lymph nodes in patients who present with primary cutaneous melanoma provides accurate staging and avoids the need for sentinel node (SN) biopsy. However, in most single institution studies the reported sensitivity for preoperative US detection of nodal metastases has been low.
Methods: Preoperative US data and SNB results were analyzed for patients enrolled at 20 centers participating in the screening phase of the second Multicenter Selective Lymphadenectomy Trial. Excised SNs were histopathologically assessed and considered positive if any melanoma was seen.
Results: SNs were identified and removed from 2786 patients who had pre-operative US evaluation. Among those patients, 531 had SN metastases. US was positive (abnormal) in 85 patients (3.1%). Among SN-positive patients, 39 (7.3%) had an abnormal US. When analyzed by lymph node basin, 3222 basins were evaluated, and 38 were true positive (1.2%). By basin, the sensitivity of US was 6.8% (95% CI: 4.7%-8.9%) and the specificity 98.0% (95% CI: 97.5%-98.5%). Median cross sectional area of all SN metastases was 0.13mm2; in US true-positive nodes it was 4.8mm2. US sensitivity increased with increasing Breslow thickness of the primary melanoma (0% for ≤1mm thickness, 12.4% for >4mm thickness). US sensitivity was not significantly greater with higher trial center volume or with pre-US lymphoscintigraphy.
Conclusion: In the MSLT-II screening phase population, SN tumor volume was usually too small to be reliably detected by US. For accurate nodal staging to guide the management of melanoma patients, US is not an effective substitute for SN biopsy.
Did you know that prostate cancer spreads to the bone in 9 out of 10 men with metastatic castration-resistant prostate cancer (mCRPC)? One of the reasons it may have spread is because the cancer is no longer responding to hormonal or surgical treatment that lowers testosterone.
Among the treatment options being utilized, there is a treatment called Xofigo® (radium Ra 223 dichloride) injection. Xofigo is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone. It is for men whose prostate cancer has spread to the bone with symptoms but not to other parts of the body.
Xofigo contains the radioactive material radium 223, which works by going to areas in the bones that are growing quickly, just like calcium does. Bone metastases are one of those rapidly growing areas. Once at the metastases, Xofigo gives off a strong energy that travels a short distance. The energy is deadly to the cancer cells in the bones but does limited damage to nearby healthy cells. Xofigo can be absorbed by other organs, primarily the bone marrow and digestive system, which may result in side effects in those healthy tissues.
Contact us at 310.264.9000 to speak to one of our radiologists about mCRPC, risk factors, symptoms and treatments like Xofigo that may be appropriate for certain patients.
You can also get more information regarding Xofigo on their website: https://www.xofigo-us.com
About Oscar Health Insurance
Based out of New York City, Oscar currently offers individual health plans in parts of New York, Texas, and California. Its aim is to change Americans’ experience of engaging with the healthcare system by redesigning insurance to be geared toward the user experience.Oscar offers all members free 24/7 telemedicine visits through their Doctor on Call service as a part of their membership, which are available both through the Oscar Android or iOS app or the Oscar web app. Oscar assigns each of its members to a “Concierge Team” which is made up of a team of three care guides and a registered nurse that handle both traditional customer service questions as well as coordination of clinical care.
In an interview with the Phoenix Business Journal in 2017, Oscar’s VP of Customer Care Paul Gazely said that Oscar’s concierge model “helps to build a relationship and build trust with our members with their health care needs,” and that the model helps Oscar familiarize itself “with the member’s needs by looking at the entire member’s health history.”
In addition, Oscar offers its members Amazon gift cards as a part of a rewards program for step tracking. Oscar offers direct appointment scheduling with a selection of its provider partners, and (as of 2017) offers in-network providers an application and tools to serve Oscar members, including a Clinical Dashboard that pulls Oscar members’ medical histories into a single platform.
During December of 2017 letters from Anthem Blue Cross were erroneously sent letters to patients notifying them that Tower Saint John’s Imaging is no longer part of their network. TSJI is still contracted with Anthem Blue Cross and is a part of their network, and is doing their best to notify all of their patients of this error.TSJI and Anthem Blue Cross apologize for any confusion and inconvenience this mistake has caused our patients.
If you have any additional questions please reach out to Anthem Blue Cross at:
Anthem.com/ca
Monday-Friday, 8 a.m. to 8 p.m. ET
1-866-755-2680
